The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bulbospinal Muscular Atrophy Drugs Market Research Report 2025
Synopsis
The global Bulbospinal Muscular Atrophy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Bulbospinal Muscular Atrophy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bulbospinal Muscular Atrophy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bulbospinal Muscular Atrophy Drugs include Novartis, F. Hoffmann-La Roche, Boehringer Ingelheim, Pfizer, Ionis Pharmaceuticals, Cytokinetics, Regeneron Pharmaceuticals, Salarius Pharmaceuticals, Leadiant Biosciences, Abbott, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bulbospinal Muscular Atrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bulbospinal Muscular Atrophy Drugs.
The Bulbospinal Muscular Atrophy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Bulbospinal Muscular Atrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bulbospinal Muscular Atrophy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novartis
F. Hoffmann-La Roche
Boehringer Ingelheim
Pfizer
Ionis Pharmaceuticals
Cytokinetics
Regeneron Pharmaceuticals
Salarius Pharmaceuticals
Leadiant Biosciences
Abbott
Novo Nordisk
Takeda Pharmaceutical
AstraZeneca
Catalyst Pharma
PTC Therapeutics
Natera
Segment by Type
Leuprorelin
Dutasteride
Other
Segment by Application
Hospital
Homecare
Specialty Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bulbospinal Muscular Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bulbospinal Muscular Atrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Bulbospinal Muscular Atrophy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Bulbospinal Muscular Atrophy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bulbospinal Muscular Atrophy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bulbospinal Muscular Atrophy Drugs include Novartis, F. Hoffmann-La Roche, Boehringer Ingelheim, Pfizer, Ionis Pharmaceuticals, Cytokinetics, Regeneron Pharmaceuticals, Salarius Pharmaceuticals, Leadiant Biosciences, Abbott, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bulbospinal Muscular Atrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bulbospinal Muscular Atrophy Drugs.
The Bulbospinal Muscular Atrophy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Bulbospinal Muscular Atrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bulbospinal Muscular Atrophy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novartis
F. Hoffmann-La Roche
Boehringer Ingelheim
Pfizer
Ionis Pharmaceuticals
Cytokinetics
Regeneron Pharmaceuticals
Salarius Pharmaceuticals
Leadiant Biosciences
Abbott
Novo Nordisk
Takeda Pharmaceutical
AstraZeneca
Catalyst Pharma
PTC Therapeutics
Natera
Segment by Type
Leuprorelin
Dutasteride
Other
Segment by Application
Hospital
Homecare
Specialty Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bulbospinal Muscular Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bulbospinal Muscular Atrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Bulbospinal Muscular Atrophy Drugs Market Overview
1.1 Product Definition
1.2 Bulbospinal Muscular Atrophy Drugs by Type
1.2.1 Global Bulbospinal Muscular Atrophy Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Leuprorelin
1.2.3 Dutasteride
1.2.4 Other
1.3 Bulbospinal Muscular Atrophy Drugs by Application
1.3.1 Global Bulbospinal Muscular Atrophy Drugs Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Homecare
1.3.4 Specialty Clinic
1.3.5 Other
1.4 Global Bulbospinal Muscular Atrophy Drugs Market Size Estimates and Forecasts
1.4.1 Global Bulbospinal Muscular Atrophy Drugs Revenue 2019-2030
1.4.2 Global Bulbospinal Muscular Atrophy Drugs Sales 2019-2030
1.4.3 Global Bulbospinal Muscular Atrophy Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bulbospinal Muscular Atrophy Drugs Market Competition by Manufacturers
2.1 Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bulbospinal Muscular Atrophy Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Bulbospinal Muscular Atrophy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bulbospinal Muscular Atrophy Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bulbospinal Muscular Atrophy Drugs, Product Type & Application
2.7 Global Key Manufacturers of Bulbospinal Muscular Atrophy Drugs, Date of Enter into This Industry
2.8 Global Bulbospinal Muscular Atrophy Drugs Market Competitive Situation and Trends
2.8.1 Global Bulbospinal Muscular Atrophy Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Bulbospinal Muscular Atrophy Drugs Players Market Share by Revenue
2.8.3 Global Bulbospinal Muscular Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bulbospinal Muscular Atrophy Drugs Market Scenario by Region
3.1 Global Bulbospinal Muscular Atrophy Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bulbospinal Muscular Atrophy Drugs Sales by Region: 2019-2030
3.2.1 Global Bulbospinal Muscular Atrophy Drugs Sales by Region: 2019-2024
3.2.2 Global Bulbospinal Muscular Atrophy Drugs Sales by Region: 2025-2030
3.3 Global Bulbospinal Muscular Atrophy Drugs Revenue by Region: 2019-2030
3.3.1 Global Bulbospinal Muscular Atrophy Drugs Revenue by Region: 2019-2024
3.3.2 Global Bulbospinal Muscular Atrophy Drugs Revenue by Region: 2025-2030
3.4 North America Bulbospinal Muscular Atrophy Drugs Market Facts & Figures by Country
3.4.1 North America Bulbospinal Muscular Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2030)
3.4.3 North America Bulbospinal Muscular Atrophy Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bulbospinal Muscular Atrophy Drugs Market Facts & Figures by Country
3.5.1 Europe Bulbospinal Muscular Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2030)
3.5.3 Europe Bulbospinal Muscular Atrophy Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bulbospinal Muscular Atrophy Drugs Sales by Region (2019-2030)
3.6.3 Asia Pacific Bulbospinal Muscular Atrophy Drugs Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bulbospinal Muscular Atrophy Drugs Market Facts & Figures by Country
3.7.1 Latin America Bulbospinal Muscular Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2030)
3.7.3 Latin America Bulbospinal Muscular Atrophy Drugs Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bulbospinal Muscular Atrophy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Bulbospinal Muscular Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bulbospinal Muscular Atrophy Drugs Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bulbospinal Muscular Atrophy Drugs Sales by Type (2019-2030)
4.1.1 Global Bulbospinal Muscular Atrophy Drugs Sales by Type (2019-2024)
4.1.2 Global Bulbospinal Muscular Atrophy Drugs Sales by Type (2025-2030)
4.1.3 Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Type (2019-2030)
4.2 Global Bulbospinal Muscular Atrophy Drugs Revenue by Type (2019-2030)
4.2.1 Global Bulbospinal Muscular Atrophy Drugs Revenue by Type (2019-2024)
4.2.2 Global Bulbospinal Muscular Atrophy Drugs Revenue by Type (2025-2030)
4.2.3 Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Bulbospinal Muscular Atrophy Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bulbospinal Muscular Atrophy Drugs Sales by Application (2019-2030)
5.1.1 Global Bulbospinal Muscular Atrophy Drugs Sales by Application (2019-2024)
5.1.2 Global Bulbospinal Muscular Atrophy Drugs Sales by Application (2025-2030)
5.1.3 Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Application (2019-2030)
5.2 Global Bulbospinal Muscular Atrophy Drugs Revenue by Application (2019-2030)
5.2.1 Global Bulbospinal Muscular Atrophy Drugs Revenue by Application (2019-2024)
5.2.2 Global Bulbospinal Muscular Atrophy Drugs Revenue by Application (2025-2030)
5.2.3 Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Bulbospinal Muscular Atrophy Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 F. Hoffmann-La Roche
6.2.1 F. Hoffmann-La Roche Company Information
6.2.2 F. Hoffmann-La Roche Description and Business Overview
6.2.3 F. Hoffmann-La Roche Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 F. Hoffmann-La Roche Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.2.5 F. Hoffmann-La Roche Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Company Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Ionis Pharmaceuticals
6.5.1 Ionis Pharmaceuticals Company Information
6.5.2 Ionis Pharmaceuticals Description and Business Overview
6.5.3 Ionis Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Ionis Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.5.5 Ionis Pharmaceuticals Recent Developments/Updates
6.6 Cytokinetics
6.6.1 Cytokinetics Company Information
6.6.2 Cytokinetics Description and Business Overview
6.6.3 Cytokinetics Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Cytokinetics Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.6.5 Cytokinetics Recent Developments/Updates
6.7 Regeneron Pharmaceuticals
6.7.1 Regeneron Pharmaceuticals Company Information
6.7.2 Regeneron Pharmaceuticals Description and Business Overview
6.7.3 Regeneron Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Regeneron Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.7.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.8 Salarius Pharmaceuticals
6.8.1 Salarius Pharmaceuticals Company Information
6.8.2 Salarius Pharmaceuticals Description and Business Overview
6.8.3 Salarius Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Salarius Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.8.5 Salarius Pharmaceuticals Recent Developments/Updates
6.9 Leadiant Biosciences
6.9.1 Leadiant Biosciences Company Information
6.9.2 Leadiant Biosciences Description and Business Overview
6.9.3 Leadiant Biosciences Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Leadiant Biosciences Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.9.5 Leadiant Biosciences Recent Developments/Updates
6.10 Abbott
6.10.1 Abbott Company Information
6.10.2 Abbott Description and Business Overview
6.10.3 Abbott Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Abbott Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.10.5 Abbott Recent Developments/Updates
6.11 Novo Nordisk
6.11.1 Novo Nordisk Company Information
6.11.2 Novo Nordisk Description and Business Overview
6.11.3 Novo Nordisk Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Novo Nordisk Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.11.5 Novo Nordisk Recent Developments/Updates
6.12 Takeda Pharmaceutical
6.12.1 Takeda Pharmaceutical Company Information
6.12.2 Takeda Pharmaceutical Description and Business Overview
6.12.3 Takeda Pharmaceutical Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Takeda Pharmaceutical Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.12.5 Takeda Pharmaceutical Recent Developments/Updates
6.13 AstraZeneca
6.13.1 AstraZeneca Company Information
6.13.2 AstraZeneca Description and Business Overview
6.13.3 AstraZeneca Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 AstraZeneca Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.13.5 AstraZeneca Recent Developments/Updates
6.14 Catalyst Pharma
6.14.1 Catalyst Pharma Company Information
6.14.2 Catalyst Pharma Description and Business Overview
6.14.3 Catalyst Pharma Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Catalyst Pharma Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.14.5 Catalyst Pharma Recent Developments/Updates
6.15 PTC Therapeutics
6.15.1 PTC Therapeutics Company Information
6.15.2 PTC Therapeutics Description and Business Overview
6.15.3 PTC Therapeutics Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 PTC Therapeutics Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.15.5 PTC Therapeutics Recent Developments/Updates
6.16 Natera
6.16.1 Natera Company Information
6.16.2 Natera Description and Business Overview
6.16.3 Natera Bulbospinal Muscular Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Natera Bulbospinal Muscular Atrophy Drugs Product Portfolio
6.16.5 Natera Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bulbospinal Muscular Atrophy Drugs Industry Chain Analysis
7.2 Bulbospinal Muscular Atrophy Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bulbospinal Muscular Atrophy Drugs Production Mode & Process
7.4 Bulbospinal Muscular Atrophy Drugs Sales and Marketing
7.4.1 Bulbospinal Muscular Atrophy Drugs Sales Channels
7.4.2 Bulbospinal Muscular Atrophy Drugs Distributors
7.5 Bulbospinal Muscular Atrophy Drugs Customers
8 Bulbospinal Muscular Atrophy Drugs Market Dynamics
8.1 Bulbospinal Muscular Atrophy Drugs Industry Trends
8.2 Bulbospinal Muscular Atrophy Drugs Market Drivers
8.3 Bulbospinal Muscular Atrophy Drugs Market Challenges
8.4 Bulbospinal Muscular Atrophy Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Bulbospinal Muscular Atrophy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Bulbospinal Muscular Atrophy Drugs Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Bulbospinal Muscular Atrophy Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Bulbospinal Muscular Atrophy Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Bulbospinal Muscular Atrophy Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Bulbospinal Muscular Atrophy Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Bulbospinal Muscular Atrophy Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Bulbospinal Muscular Atrophy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Bulbospinal Muscular Atrophy Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Bulbospinal Muscular Atrophy Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Bulbospinal Muscular Atrophy Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bulbospinal Muscular Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bulbospinal Muscular Atrophy Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bulbospinal Muscular Atrophy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Bulbospinal Muscular Atrophy Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Bulbospinal Muscular Atrophy Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Bulbospinal Muscular Atrophy Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Bulbospinal Muscular Atrophy Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Bulbospinal Muscular Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Bulbospinal Muscular Atrophy Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Bulbospinal Muscular Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Bulbospinal Muscular Atrophy Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Bulbospinal Muscular Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Bulbospinal Muscular Atrophy Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Bulbospinal Muscular Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Bulbospinal Muscular Atrophy Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Bulbospinal Muscular Atrophy Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Bulbospinal Muscular Atrophy Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Bulbospinal Muscular Atrophy Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Bulbospinal Muscular Atrophy Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Bulbospinal Muscular Atrophy Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Bulbospinal Muscular Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Bulbospinal Muscular Atrophy Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Bulbospinal Muscular Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Bulbospinal Muscular Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Bulbospinal Muscular Atrophy Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East and Africa Bulbospinal Muscular Atrophy Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East and Africa Bulbospinal Muscular Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Bulbospinal Muscular Atrophy Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Bulbospinal Muscular Atrophy Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Bulbospinal Muscular Atrophy Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Bulbospinal Muscular Atrophy Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Bulbospinal Muscular Atrophy Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Bulbospinal Muscular Atrophy Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Bulbospinal Muscular Atrophy Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Bulbospinal Muscular Atrophy Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Bulbospinal Muscular Atrophy Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Bulbospinal Muscular Atrophy Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Bulbospinal Muscular Atrophy Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Bulbospinal Muscular Atrophy Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Bulbospinal Muscular Atrophy Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Bulbospinal Muscular Atrophy Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. Novartis Company Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Novartis Bulbospinal Muscular Atrophy Drugs Product
Table 74. Novartis Recent Developments/Updates
Table 75. F. Hoffmann-La Roche Company Information
Table 76. F. Hoffmann-La Roche Description and Business Overview
Table 77. F. Hoffmann-La Roche Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. F. Hoffmann-La Roche Bulbospinal Muscular Atrophy Drugs Product
Table 79. F. Hoffmann-La Roche Recent Developments/Updates
Table 80. Boehringer Ingelheim Company Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Boehringer Ingelheim Bulbospinal Muscular Atrophy Drugs Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Pfizer Bulbospinal Muscular Atrophy Drugs Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Ionis Pharmaceuticals Company Information
Table 91. Ionis Pharmaceuticals Description and Business Overview
Table 92. Ionis Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Ionis Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Product
Table 94. Ionis Pharmaceuticals Recent Developments/Updates
Table 95. Cytokinetics Company Information
Table 96. Cytokinetics Description and Business Overview
Table 97. Cytokinetics Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Cytokinetics Bulbospinal Muscular Atrophy Drugs Product
Table 99. Cytokinetics Recent Developments/Updates
Table 100. Regeneron Pharmaceuticals Company Information
Table 101. Regeneron Pharmaceuticals Description and Business Overview
Table 102. Regeneron Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Regeneron Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Product
Table 104. Regeneron Pharmaceuticals Recent Developments/Updates
Table 105. Salarius Pharmaceuticals Company Information
Table 106. Salarius Pharmaceuticals Description and Business Overview
Table 107. Salarius Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Salarius Pharmaceuticals Bulbospinal Muscular Atrophy Drugs Product
Table 109. Salarius Pharmaceuticals Recent Developments/Updates
Table 110. Leadiant Biosciences Company Information
Table 111. Leadiant Biosciences Description and Business Overview
Table 112. Leadiant Biosciences Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Leadiant Biosciences Bulbospinal Muscular Atrophy Drugs Product
Table 114. Leadiant Biosciences Recent Developments/Updates
Table 115. Abbott Company Information
Table 116. Abbott Description and Business Overview
Table 117. Abbott Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Abbott Bulbospinal Muscular Atrophy Drugs Product
Table 119. Abbott Recent Developments/Updates
Table 120. Novo Nordisk Company Information
Table 121. Novo Nordisk Description and Business Overview
Table 122. Novo Nordisk Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Novo Nordisk Bulbospinal Muscular Atrophy Drugs Product
Table 124. Novo Nordisk Recent Developments/Updates
Table 125. Takeda Pharmaceutical Company Information
Table 126. Takeda Pharmaceutical Description and Business Overview
Table 127. Takeda Pharmaceutical Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Takeda Pharmaceutical Bulbospinal Muscular Atrophy Drugs Product
Table 129. Takeda Pharmaceutical Recent Developments/Updates
Table 130. AstraZeneca Company Information
Table 131. AstraZeneca Description and Business Overview
Table 132. AstraZeneca Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. AstraZeneca Bulbospinal Muscular Atrophy Drugs Product
Table 134. AstraZeneca Recent Developments/Updates
Table 135. Catalyst Pharma Company Information
Table 136. Catalyst Pharma Description and Business Overview
Table 137. Catalyst Pharma Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Catalyst Pharma Bulbospinal Muscular Atrophy Drugs Product
Table 139. Catalyst Pharma Recent Developments/Updates
Table 140. PTC Therapeutics Company Information
Table 141. PTC Therapeutics Description and Business Overview
Table 142. PTC Therapeutics Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. PTC Therapeutics Bulbospinal Muscular Atrophy Drugs Product
Table 144. PTC Therapeutics Recent Developments/Updates
Table 145. Natera Company Information
Table 146. Natera Description and Business Overview
Table 147. Natera Bulbospinal Muscular Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Natera Bulbospinal Muscular Atrophy Drugs Product
Table 149. Natera Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Bulbospinal Muscular Atrophy Drugs Distributors List
Table 153. Bulbospinal Muscular Atrophy Drugs Customers List
Table 154. Bulbospinal Muscular Atrophy Drugs Market Trends
Table 155. Bulbospinal Muscular Atrophy Drugs Market Drivers
Table 156. Bulbospinal Muscular Atrophy Drugs Market Challenges
Table 157. Bulbospinal Muscular Atrophy Drugs Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Bulbospinal Muscular Atrophy Drugs
Figure 2. Global Bulbospinal Muscular Atrophy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Bulbospinal Muscular Atrophy Drugs Market Share by Type: 2023 & 2030
Figure 4. Leuprorelin Product Picture
Figure 5. Dutasteride Product Picture
Figure 6. Other Product Picture
Figure 7. Global Bulbospinal Muscular Atrophy Drugs Market Value by Application (2024-2030) & (US$ Million)
Figure 8. Global Bulbospinal Muscular Atrophy Drugs Market Share by Application: 2023 & 2030
Figure 9. Hospital
Figure 10. Homecare
Figure 11. Specialty Clinic
Figure 12. Other
Figure 13. Global Bulbospinal Muscular Atrophy Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Bulbospinal Muscular Atrophy Drugs Market Size (2019-2030) & (US$ Million)
Figure 15. Global Bulbospinal Muscular Atrophy Drugs Sales (2019-2030) & (K Units)
Figure 16. Global Bulbospinal Muscular Atrophy Drugs Average Price (US$/Unit) & (2019-2030)
Figure 17. Bulbospinal Muscular Atrophy Drugs Report Years Considered
Figure 18. Bulbospinal Muscular Atrophy Drugs Sales Share by Manufacturers in 2023
Figure 19. Global Bulbospinal Muscular Atrophy Drugs Revenue Share by Manufacturers in 2023
Figure 20. Global 5 and 10 Largest Bulbospinal Muscular Atrophy Drugs Players: Market Share by Revenue in Bulbospinal Muscular Atrophy Drugs in 2023
Figure 21. Bulbospinal Muscular Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 22. Global Bulbospinal Muscular Atrophy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Bulbospinal Muscular Atrophy Drugs Sales Market Share by Country (2019-2030)
Figure 24. North America Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Country (2019-2030)
Figure 25. United States Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Bulbospinal Muscular Atrophy Drugs Sales Market Share by Country (2019-2030)
Figure 28. Europe Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Country (2019-2030)
Figure 29. Germany Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Bulbospinal Muscular Atrophy Drugs Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Region (2019-2030)
Figure 36. China Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Bulbospinal Muscular Atrophy Drugs Sales Market Share by Country (2019-2030)
Figure 44. Mexico Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Colombia Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East and Africa Bulbospinal Muscular Atrophy Drugs Sales Market Share by Country (2019-2030)
Figure 49. Middle East and Africa Bulbospinal Muscular Atrophy Drugs Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Bulbospinal Muscular Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Bulbospinal Muscular Atrophy Drugs by Type (2019-2030)
Figure 54. Global Revenue Market Share of Bulbospinal Muscular Atrophy Drugs by Type (2019-2030)
Figure 55. Global Bulbospinal Muscular Atrophy Drugs Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Bulbospinal Muscular Atrophy Drugs by Application (2019-2030)
Figure 57. Global Revenue Market Share of Bulbospinal Muscular Atrophy Drugs by Application (2019-2030)
Figure 58. Global Bulbospinal Muscular Atrophy Drugs Price (US$/Unit) by Application (2019-2030)
Figure 59. Bulbospinal Muscular Atrophy Drugs Value Chain
Figure 60. Bulbospinal Muscular Atrophy Drugs Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
